Merck KGaA is selling five U.S. contract manufacturing sites to streamline its manufacturing footprint. The report gives no sale price or effect on Merck's sales or profit, so it does not point clearly up or down.
The sale trims Merck KGaA's manufacturing footprint, but the report gives no sale price or effect on its sales or profit. The forecast update concerns Lonza, so the report does not show whether the sale helps or hurts Merck.
Follow Merck KGaA (MRK) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MRK